Skip to main content
Top
Published in: Drugs & Aging 12/2004

01-10-2004 | Therapy In Practice

Management of Autoimmune Skin Disorders in the Elderly

Authors: Dr Wei Jing Loo, Nigel P. Burrows

Published in: Drugs & Aging | Issue 12/2004

Login to get access

Abstract

Senescence of the skin immunological system may explain why the elderly population has an increased susceptibility to certain autoimmune skin disorders. These disorders are characterised by the production of either antibodies that react with host tissue or immune effector T cells that are autoreactive.
Bullous pemphigoid is the most common autoimmune blistering disease in the elderly. Although oral corticosteroids are the best established therapy, high-potency topical corticosteroids are very useful as initial treatment and, in the elderly, should be used instead of oral prednisolone wherever possible. Pemphigus is a chronic blistering disease of which there are two main subtypes: vulgaris and foliaceous. Paraneoplastic pemphigus is a unique clinical, histological and immunologically distinct autoimmune mucocutaneous disease which tends to be relentlessly progressive.
Lichen sclerosus presents specific complications and a small but definite increased risk of squamous cell carcinoma in elderly patients. It is important to be aware of practical issues such as the difficulty in applying topical corticosteroids, the mainstay treatment of this condition.
Dermatomyositis is an autoimmune systemic disorder where the skin and muscles are the most commonly affected organs. Tumour-associated disease occurs more commonly in elderly patients and has a poorer prognosis. Management of the disease includes sunscreens, topical or systemic corticosteroids, antimalarials, oral immunosuppressants or intravenous immunoglobulins.
It is important to bear in mind that old age modifies the management of skin diseases because of physical and social circumstances as well as the unwanted adverse effects of medications. Polypharmacy results in an increased risk of drug interactions and, therefore, drug regimens need to be kept as simple as possible. Drug-induced autoimmune skin eruptions are common amongst the elderly and usually resolve when the offending drug is discontinued.
Literature
1.
go back to reference Sunderkotter C, Kalden H, Luger TA. Aging and the skin immune system. Arch Dermatol 1997; 133(10): 1256–62PubMedCrossRef Sunderkotter C, Kalden H, Luger TA. Aging and the skin immune system. Arch Dermatol 1997; 133(10): 1256–62PubMedCrossRef
2.
go back to reference Gilchrest BA, Murphy GF, Soter NA. Effect of chronologic ageing and ultraviolet irradiation on Langerhan cells in human epidermis. J Invest Dermatol 1982; 79: 85–8PubMedCrossRef Gilchrest BA, Murphy GF, Soter NA. Effect of chronologic ageing and ultraviolet irradiation on Langerhan cells in human epidermis. J Invest Dermatol 1982; 79: 85–8PubMedCrossRef
3.
go back to reference Report on the enquiry into skin diseases in elderly people: a report of the Associate Parliamentary Group on the Skin. London: Portcullis Research, 2000 Nov Report on the enquiry into skin diseases in elderly people: a report of the Associate Parliamentary Group on the Skin. London: Portcullis Research, 2000 Nov
4.
go back to reference Bernard P, Vaillant L, Labeille B, et al. Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Arch Dermatol 1995; 131: 48–52PubMedCrossRef Bernard P, Vaillant L, Labeille B, et al. Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Arch Dermatol 1995; 131: 48–52PubMedCrossRef
5.
go back to reference Zillikens D, Wever S, Roth A, et al. Incidence of autoimmune subepidermal blistering dermatoses in a region of Central Germany. Arch Dermatol 1995; 131: 957–8PubMedCrossRef Zillikens D, Wever S, Roth A, et al. Incidence of autoimmune subepidermal blistering dermatoses in a region of Central Germany. Arch Dermatol 1995; 131: 957–8PubMedCrossRef
6.
go back to reference Anhalt G, Bahn C, Labib R, et al. Pathogenic effects of bullous pemphigoid autoantibodies on rabbit corneal epithelium. J Clin Invest 1981; 68: 1097–101PubMedCrossRef Anhalt G, Bahn C, Labib R, et al. Pathogenic effects of bullous pemphigoid autoantibodies on rabbit corneal epithelium. J Clin Invest 1981; 68: 1097–101PubMedCrossRef
7.
go back to reference Liu Z, Diaz L, Troy J, et al. A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen BP180. J Clin Invest 1993; 92: 2480–8PubMedCrossRef Liu Z, Diaz L, Troy J, et al. A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen BP180. J Clin Invest 1993; 92: 2480–8PubMedCrossRef
8.
go back to reference Diaz L, Weiss H, Calcanico N. Phylogenetic studies with pemphigus and pemphigoid antibodies. Acta Derm Venereol (Stockh) 1978; 58: 535–9 Diaz L, Weiss H, Calcanico N. Phylogenetic studies with pemphigus and pemphigoid antibodies. Acta Derm Venereol (Stockh) 1978; 58: 535–9
9.
go back to reference Westerhof W. Treatment of bullous pemphigoid with topical clobetasol propionate. J Am Acad Dermatol 1989; 20: 458–61PubMedCrossRef Westerhof W. Treatment of bullous pemphigoid with topical clobetasol propionate. J Am Acad Dermatol 1989; 20: 458–61PubMedCrossRef
10.
go back to reference Joly P, Roujeau JC, Benichou J, etal. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med 2002; 346(5): 321–7PubMedCrossRef Joly P, Roujeau JC, Benichou J, etal. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med 2002; 346(5): 321–7PubMedCrossRef
11.
go back to reference Fivenson D, Breneman D, Rosen G, et al. Nicotinamide and tetracycline therapy of bullous pemphigoid. Arch Dermatol 1994; 130: 753–8PubMedCrossRef Fivenson D, Breneman D, Rosen G, et al. Nicotinamide and tetracycline therapy of bullous pemphigoid. Arch Dermatol 1994; 130: 753–8PubMedCrossRef
12.
go back to reference Kawahara Y, Hashimoto T, Ohata Y, et al. Eleven cases of bullous pemphigoid treated with a combination of minocycline and nicotinamide. Eur J Dermatol 1996; 6: 427–9 Kawahara Y, Hashimoto T, Ohata Y, et al. Eleven cases of bullous pemphigoid treated with a combination of minocycline and nicotinamide. Eur J Dermatol 1996; 6: 427–9
13.
go back to reference Fox BJ, Odom RB, Findlay RF. Erythromycin therapy in bullous pemphigoid: possible anti-inflammatory effects. J Am Acad Dermatol 1982; 7: 504–10PubMedCrossRef Fox BJ, Odom RB, Findlay RF. Erythromycin therapy in bullous pemphigoid: possible anti-inflammatory effects. J Am Acad Dermatol 1982; 7: 504–10PubMedCrossRef
14.
go back to reference Burton JL, Harman RR, Peachy RD, et al. Azathioprine plus prednisolone in treatment of pemphigoid. BMJ 1978; 2: 1190–1PubMedCrossRef Burton JL, Harman RR, Peachy RD, et al. Azathioprine plus prednisolone in treatment of pemphigoid. BMJ 1978; 2: 1190–1PubMedCrossRef
15.
go back to reference Guillaume JC, Vaillant L, Bernard P, et al. Controlled trial of azathioprine and plasma exchange in addition to prednisolone in the treatment of bullous pemphigoid. Arch Dermatol 1993; 129: 49–53PubMedCrossRef Guillaume JC, Vaillant L, Bernard P, et al. Controlled trial of azathioprine and plasma exchange in addition to prednisolone in the treatment of bullous pemphigoid. Arch Dermatol 1993; 129: 49–53PubMedCrossRef
16.
go back to reference Bouscarat F, Chosidow O, Picard-Dahan C, et al. Treatment of bullous pemphigoid with dapsone: retrospective study of thirty-six cases. J Am Acad Dermatol 1996; 34: 683–4PubMedCrossRef Bouscarat F, Chosidow O, Picard-Dahan C, et al. Treatment of bullous pemphigoid with dapsone: retrospective study of thirty-six cases. J Am Acad Dermatol 1996; 34: 683–4PubMedCrossRef
17.
go back to reference Itoh T, Hosokawa H, Shirai Y, et al. Successful treatment of bullous pemphigoid with pulsed intravenous cyclophosphamide. Br J Dermatol 1996; 134: 931–3PubMedCrossRef Itoh T, Hosokawa H, Shirai Y, et al. Successful treatment of bullous pemphigoid with pulsed intravenous cyclophosphamide. Br J Dermatol 1996; 134: 931–3PubMedCrossRef
18.
go back to reference Heilborn JD, Stahle-Backdahl M, Albertioni F, et al. Low dose oral pulse methotrexate as monotherapy in elderly patients with bullous pemphigoid. J Am Acad Dermatol 1999; 40: 741–9PubMedCrossRef Heilborn JD, Stahle-Backdahl M, Albertioni F, et al. Low dose oral pulse methotrexate as monotherapy in elderly patients with bullous pemphigoid. J Am Acad Dermatol 1999; 40: 741–9PubMedCrossRef
19.
go back to reference Barthelemy H, Thivolet J, Cambazard F, et al. Cyclosporine in the treatment of bullous pemphigoid: preliminary study. Ann Dermatol Venereol 1986; 113: 309–13PubMed Barthelemy H, Thivolet J, Cambazard F, et al. Cyclosporine in the treatment of bullous pemphigoid: preliminary study. Ann Dermatol Venereol 1986; 113: 309–13PubMed
20.
go back to reference Harman KE, Black MM. High dose intravenous immune globulin for the treatment of autoimmune blistering diseases: an evaluation of its use in 14 cases. Br J Dermatol 1999; 140: 865–74PubMedCrossRef Harman KE, Black MM. High dose intravenous immune globulin for the treatment of autoimmune blistering diseases: an evaluation of its use in 14 cases. Br J Dermatol 1999; 140: 865–74PubMedCrossRef
21.
go back to reference Egan CA, Meadows KP, Zone JJ. Plasmapheresis as a steroid saving procedure in bullous pemphigoid. Int J Dermatol 2000; 39: 230–5PubMedCrossRef Egan CA, Meadows KP, Zone JJ. Plasmapheresis as a steroid saving procedure in bullous pemphigoid. Int J Dermatol 2000; 39: 230–5PubMedCrossRef
22.
go back to reference Jan V, Callens A, Machet MC, et al. D-penicillamine-induced pemphigus, polymyositis and myasthenia. Ann Dermatol Venereol 1999; 126(2): 153–6PubMed Jan V, Callens A, Machet MC, et al. D-penicillamine-induced pemphigus, polymyositis and myasthenia. Ann Dermatol Venereol 1999; 126(2): 153–6PubMed
23.
go back to reference Wojnarowska F, Eady RAJ, Burge S. Bullous eruptions. In: Champion RH, Burton JL, Ebling FJG, editors. Textbook of dermatology. 6th ed. Vol. 3. Oxford: Blackwell Scientific Publications, 1998: 1817–98 Wojnarowska F, Eady RAJ, Burge S. Bullous eruptions. In: Champion RH, Burton JL, Ebling FJG, editors. Textbook of dermatology. 6th ed. Vol. 3. Oxford: Blackwell Scientific Publications, 1998: 1817–98
24.
go back to reference Fitzpatrick RE, Newcomer VD. The correlation of disease activity and antibody titres in pemphigus. Arch Dermatol 1980; 116: 285–90PubMedCrossRef Fitzpatrick RE, Newcomer VD. The correlation of disease activity and antibody titres in pemphigus. Arch Dermatol 1980; 116: 285–90PubMedCrossRef
25.
go back to reference Iwatsuki K, Takigawa M, Jin F, et al. Ultrastructural binding site of pemphigus foliaceous autoantibodies: comparison with pemphigus vulgaris. J Cutan Pathol 1991; 18: 160–3PubMedCrossRef Iwatsuki K, Takigawa M, Jin F, et al. Ultrastructural binding site of pemphigus foliaceous autoantibodies: comparison with pemphigus vulgaris. J Cutan Pathol 1991; 18: 160–3PubMedCrossRef
26.
go back to reference Rosenberg FR, Sanders S, Nelson CT. Pemphigus: a 20 year review of 107 patients treated with corticosteroids. Arch Dermatol 1976; 112: 962–70PubMedCrossRef Rosenberg FR, Sanders S, Nelson CT. Pemphigus: a 20 year review of 107 patients treated with corticosteroids. Arch Dermatol 1976; 112: 962–70PubMedCrossRef
27.
go back to reference Aberer W, Wolff-Schreiner EC, Stingl G, et al. Azathioprine in the treatment of pemphigus vulgaris: a long term follow-up. J Am Acad Dermatol 1987; 16: 527–33PubMedCrossRef Aberer W, Wolff-Schreiner EC, Stingl G, et al. Azathioprine in the treatment of pemphigus vulgaris: a long term follow-up. J Am Acad Dermatol 1987; 16: 527–33PubMedCrossRef
28.
go back to reference Tavadia SM, Mydlarski PR, Reis MD, et al. Screening for azathioprine toxicity: a pharmacoeconomic analysis based on a target case. J Am Acad Dermatol 2000; 42(4): 628–32PubMed Tavadia SM, Mydlarski PR, Reis MD, et al. Screening for azathioprine toxicity: a pharmacoeconomic analysis based on a target case. J Am Acad Dermatol 2000; 42(4): 628–32PubMed
29.
go back to reference Enk AH, Knop J. Mycophenolate mofetil is effective in the treatment of pemphigus vulgaris. Arch Dermatol 1999; 135: 54–6PubMedCrossRef Enk AH, Knop J. Mycophenolate mofetil is effective in the treatment of pemphigus vulgaris. Arch Dermatol 1999; 135: 54–6PubMedCrossRef
30.
go back to reference Pasricha JS, Khaitan BK, Raman RS, et al. Dexamethasone-cyclophosphamide pulse therapy for pemphigus. Int J Dermatol 1995; 34: 875–82PubMedCrossRef Pasricha JS, Khaitan BK, Raman RS, et al. Dexamethasone-cyclophosphamide pulse therapy for pemphigus. Int J Dermatol 1995; 34: 875–82PubMedCrossRef
31.
go back to reference Roujeau JC, Andre C, Fabre MJ, et al. Plasma exchange in pemphigus. Arch Dermatol 1983; 119: 215–21PubMedCrossRef Roujeau JC, Andre C, Fabre MJ, et al. Plasma exchange in pemphigus. Arch Dermatol 1983; 119: 215–21PubMedCrossRef
32.
go back to reference Huilgol SC, Black MM. Management of the immunobullous disorders: II. Pemphigus. Clin Exp Dermatol 1995; 20: 283–93PubMedCrossRef Huilgol SC, Black MM. Management of the immunobullous disorders: II. Pemphigus. Clin Exp Dermatol 1995; 20: 283–93PubMedCrossRef
33.
go back to reference Callen JP. Internal disorders associated with bullous disease of the skin: a critical review. J Am Acad Dermatol 1980; 3(2): 107–19PubMedCrossRef Callen JP. Internal disorders associated with bullous disease of the skin: a critical review. J Am Acad Dermatol 1980; 3(2): 107–19PubMedCrossRef
34.
go back to reference Nousari HC, Anhalt GJ. Pemphigus. In: Lebwohl M, Heymann WR, Berth-Jones J, et al., editors. Treatment of skin disease. 1st ed. London: Harcourt Publishers Limited, 2002: 452–3 Nousari HC, Anhalt GJ. Pemphigus. In: Lebwohl M, Heymann WR, Berth-Jones J, et al., editors. Treatment of skin disease. 1st ed. London: Harcourt Publishers Limited, 2002: 452–3
35.
go back to reference Horn TD, Anhalt GJ. Histologic features of paraneoplastic pemphigus. Arch Dermatol 1992; 128(8): 1091–5PubMedCrossRef Horn TD, Anhalt GJ. Histologic features of paraneoplastic pemphigus. Arch Dermatol 1992; 128(8): 1091–5PubMedCrossRef
36.
go back to reference Farrell AM, Marren P, Dean D, et al. Lichen sclerosus: evidence that immunological changes occur at all levels of the skin. Br J Dermatol 1999; 140: 1087–92PubMedCrossRef Farrell AM, Marren P, Dean D, et al. Lichen sclerosus: evidence that immunological changes occur at all levels of the skin. Br J Dermatol 1999; 140: 1087–92PubMedCrossRef
37.
go back to reference Oyama N, Chan I, Neill S, et al. Autoantibodies to extracellular matrix protein 1 in lichen sclerosus. Lancet 2003; 362: 118–23PubMedCrossRef Oyama N, Chan I, Neill S, et al. Autoantibodies to extracellular matrix protein 1 in lichen sclerosus. Lancet 2003; 362: 118–23PubMedCrossRef
38.
go back to reference Derrick EK, Ridley CM, Kobza-Black A, et al. A clinical study of 23 cases of female anogenital carcinoma. Br J Dermatol 2000; 143: 1217–23PubMedCrossRef Derrick EK, Ridley CM, Kobza-Black A, et al. A clinical study of 23 cases of female anogenital carcinoma. Br J Dermatol 2000; 143: 1217–23PubMedCrossRef
39.
go back to reference Leibowitch M, Neill S, Pelisse M, et al. The epithelial changes associated with squamous cell carcinoma of the vulva: a review of the clinical, histologic and viral findings in 78 women. Br J Obstet Gynaecol 1990; 97: 1135–9PubMedCrossRef Leibowitch M, Neill S, Pelisse M, et al. The epithelial changes associated with squamous cell carcinoma of the vulva: a review of the clinical, histologic and viral findings in 78 women. Br J Obstet Gynaecol 1990; 97: 1135–9PubMedCrossRef
40.
go back to reference Dalziel K, Millard PR, Wojnarowska F. The treatment of vulval lichen sclerosus with a very potent topical corticosteroid (clobetasol propionate 0.05%) cream. Br J Dermatol 1991; 124: 461–4PubMedCrossRef Dalziel K, Millard PR, Wojnarowska F. The treatment of vulval lichen sclerosus with a very potent topical corticosteroid (clobetasol propionate 0.05%) cream. Br J Dermatol 1991; 124: 461–4PubMedCrossRef
41.
go back to reference Rowell NR, Goodfield MJD. The connective tissue diseases. In: Champion RH, Burton JL, Ebling FJG, editors. Textbook of dermatology. 6th ed. Vol. 3. Oxford: Blackwell Scientific Publications, 1998: 2437–575 Rowell NR, Goodfield MJD. The connective tissue diseases. In: Champion RH, Burton JL, Ebling FJG, editors. Textbook of dermatology. 6th ed. Vol. 3. Oxford: Blackwell Scientific Publications, 1998: 2437–575
42.
go back to reference Sullivan DB. Detmatomyositis. In: Cassidy JT, editor. Textbook of paediatric rheumatology. 1st ed. New York: Wiley, 1983: 407 Sullivan DB. Detmatomyositis. In: Cassidy JT, editor. Textbook of paediatric rheumatology. 1st ed. New York: Wiley, 1983: 407
43.
go back to reference Hill CL, Zhang Y, Sigurgeirsson B, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 2001; 357(9250): 96–100PubMedCrossRef Hill CL, Zhang Y, Sigurgeirsson B, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 2001; 357(9250): 96–100PubMedCrossRef
44.
go back to reference Wakata N, Kurihara T, Saito E, et al. Polymyositis and dermatomyositis associated with malignancy: a 30 year retrospective study. Int J Dermatol 2002; 41: 729–34PubMedCrossRef Wakata N, Kurihara T, Saito E, et al. Polymyositis and dermatomyositis associated with malignancy: a 30 year retrospective study. Int J Dermatol 2002; 41: 729–34PubMedCrossRef
45.
go back to reference Sparsa A, Liozon E, Herrmann F, et al. Routine vs extensive malignancy search for adult dermatomyositis and polymyositis. Arch Dermatol 2002; 138: 885–90PubMedCrossRef Sparsa A, Liozon E, Herrmann F, et al. Routine vs extensive malignancy search for adult dermatomyositis and polymyositis. Arch Dermatol 2002; 138: 885–90PubMedCrossRef
46.
go back to reference Callen J. Dermatomyositis. In: Lebwohl M, Heymann WR, Berth-Jones J, et al., editors. Treatment of skin disease. 1st ed. London: Harcourt Publishers Limited, 2002: 157–60 Callen J. Dermatomyositis. In: Lebwohl M, Heymann WR, Berth-Jones J, et al., editors. Treatment of skin disease. 1st ed. London: Harcourt Publishers Limited, 2002: 157–60
47.
go back to reference Stein M, Bell MJ, Ang LC. Hydroxychloroquine neuromyotoxicity. J Rheumatol 2000; 27: 2927–31PubMed Stein M, Bell MJ, Ang LC. Hydroxychloroquine neuromyotoxicity. J Rheumatol 2000; 27: 2927–31PubMed
48.
go back to reference Russell GI, Bing RF, Jones JA, et al. Hydralazine sensitivity: clinical features, autoantibody changes and HLA-DR pheno-type. Q J Med 1987; 65(246): 845–52PubMed Russell GI, Bing RF, Jones JA, et al. Hydralazine sensitivity: clinical features, autoantibody changes and HLA-DR pheno-type. Q J Med 1987; 65(246): 845–52PubMed
49.
go back to reference Matzner Y, Erlich HA, Brautbar C, et al. Identical HLA class II alleles predispose to drug-triggered and idiopathic pemphigus vulgaris. Acta Derm Venereol 1995; 75(1) 12–4PubMed Matzner Y, Erlich HA, Brautbar C, et al. Identical HLA class II alleles predispose to drug-triggered and idiopathic pemphigus vulgaris. Acta Derm Venereol 1995; 75(1) 12–4PubMed
50.
go back to reference Brion PH, Mittal-Henkle A, Kalunian KC. Autoimmune skin rashes associated with Etanercept for rheumatoid arthritis [letter]. Ann Intern Med 1999; 131(8): 634PubMed Brion PH, Mittal-Henkle A, Kalunian KC. Autoimmune skin rashes associated with Etanercept for rheumatoid arthritis [letter]. Ann Intern Med 1999; 131(8): 634PubMed
Metadata
Title
Management of Autoimmune Skin Disorders in the Elderly
Authors
Dr Wei Jing Loo
Nigel P. Burrows
Publication date
01-10-2004
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 12/2004
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.2165/00002512-200421120-00002

Other articles of this Issue 12/2004

Drugs & Aging 12/2004 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.